Similar articles for PMID: 17631740

Year	Number of Results
2001	2
2003	5
2004	3
2005	5
2006	10
2007	17
2008	12
2009	18
2010	13
2011	12
2012	19
2013	14
2014	8
2015	4
2016	4
2017	3
2018	1
2019	3
2020	1
2021	2
2024	0

1

Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers.

Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, Dougados M. Ruyssen-Witrand A, et al. Clin Exp Rheumatol. 2007 May-Jun;25(3):430-6. Clin Exp Rheumatol. 2007. PMID: 17631740

2

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ. Schabert VF, et al. J Manag Care Pharm. 2013 Oct;19(8):621-30. doi: 10.18553/jmcp.2013.19.8.621. J Manag Care Pharm. 2013. PMID: 24074008 Free PMC article.

3

Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy.

Bibbo C, Goldberg JW. Bibbo C, et al. Foot Ankle Int. 2004 May;25(5):331-5. doi: 10.1177/107110070402500510. Foot Ankle Int. 2004. PMID: 15134615 Clinical Trial.

4

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.

Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Dixon WG, et al. Arthritis Rheum. 2006 Aug;54(8):2368-76. doi: 10.1002/art.21978. Arthritis Rheum. 2006. PMID: 16868999 Free article.

5

Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Strangfeld A, et al. JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146. JAMA. 2009. PMID: 19224750

6

Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.

Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA. Markatseli TE, et al. Clin Exp Rheumatol. 2012 Jan-Feb;30(1):31-8. Epub 2012 Mar 6. Clin Exp Rheumatol. 2012. PMID: 22153557

7

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.

Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW. Markenson JA, et al. J Rheumatol. 2011 Jul;38(7):1273-81. doi: 10.3899/jrheum.101142. Epub 2011 May 15. J Rheumatol. 2011. PMID: 21572150

8

Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.

Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register. Hyrich KL, et al. Arthritis Rheum. 2007 Jan;56(1):13-20. doi: 10.1002/art.22331. Arthritis Rheum. 2007. PMID: 17195186 Free article.

9

Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients.

Duclos M, Gossec L, Ruyssen-Witrand A, Salliot C, Luc M, Guignard S, Dougados M. Duclos M, et al. J Rheumatol. 2006 Dec;33(12):2433-8. Epub 2006 Oct 1. J Rheumatol. 2006. PMID: 17014004

10

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Ollendorf DA, Klingman D, Hazard E, Ray S. Ollendorf DA, et al. Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002. Clin Ther. 2009. PMID: 19446156

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

133 results

Results by year